Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock par value $0.012 per share
-
Shares outstanding
-
41M
-
Number of holders
-
80
-
Total 13F shares, excl. options
-
6.65M
-
Shares change
-
-2.53M
-
Total reported value, excl. options
-
$30.2M
-
Value change
-
-$18.7M
-
Put/Call ratio
-
0.24
-
Number of buys
-
40
-
Number of sells
-
-46
-
Price
-
$4.58
Significant Holders of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) as of Q2 2022
117 filings reported holding ORMP - ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share as of Q2 2022.
ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) has 80 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.65M shares
of 41M outstanding shares and own 16.21% of the company stock.
Largest 10 shareholders include MORGAN STANLEY (687K shares), TWO SIGMA ADVISERS, LP (682K shares), CITADEL ADVISORS LLC (649K shares), TWO SIGMA INVESTMENTS, LP (640K shares), MILLENNIUM MANAGEMENT LLC (580K shares), RENAISSANCE TECHNOLOGIES LLC (360K shares), JPMORGAN CHASE & CO (337K shares), MORGAN JESS S & CO INC (315K shares), BANK OF MONTREAL /CAN/ (249K shares), and Ergoteles LLC (225K shares).
This table shows the top 80 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.